Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea

Related Videos

Why is hybrid capture-based sequencing the optimal molecular profiling platform in precision cancer medicine? Can you use lung cancer as an example of how NGS can generate drug alignments? (Korean) Video

Why is hybrid capture-based sequencing the optimal molecular profiling platform in precision cancer medicine? Can you use lung cancer as an example of how NGS can generate drug alignments? (Korean)

Why is hybrid capture-based sequencing the optimal molecular profiling platform in the context of precision cancer medicine? And can you use long cancer as an example of how NGS can generate specific drug alignments?

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean) Video

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean)

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy?

What is the value of molecular profiling in the first line setting? (Korean) Video

What is the value of molecular profiling in the first line setting? (Korean)

What is the value of molecular profiling in the first line setting?

In what spectrum of tumors and at what point in the natural history of the disease do you use NGS-based molecular profiling? (Korean) Video

In what spectrum of tumors and at what point in the natural history of the disease do you use NGS-based molecular profiling? (Korean)

In what spectrum of tumors and at what point in the natural history of the disease do you use NGS-based molecular profiling?

How do the capabilities of NGS compare to hot spot testing, and why is whole exome sequencing based on hot spot panels preferred in the setting of precision oncology practice? (Korean) Video

How do the capabilities of NGS compare to hot spot testing, and why is whole exome sequencing based on hot spot panels preferred in the setting of precision oncology practice? (Korean)

How do the capabilities of NGS compare to hot spot testing, and why is whole exome sequencing based on hot spot panels preferred in the setting of precision oncology practice?

In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC? (Korean) Video

In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC? (Korean)

In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC?

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib? Video

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?

What is the importance of NGS for finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected? Video

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected?

What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase (ROS1) as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected?

In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean) Video

In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean)

In what kind of solid tumors, specifically NSCLC, can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations—ALK, MET, ROS-1—that may be missed by hotspot tests?